Boehringer Ingelheim

This study checks whether survodutide, a new weight-loss injection, affects heart rhythm in 110 overweight or obese adults. Participants receive survodutide or placebo for about 30 weeks, with heart tests before and after. The goal is to see if the drug is safe for the heart, not…

This phase 2 study tested whether adding spesolimab to standard TNF inhibitor therapy could help heal the gut lining in people with mild-to-moderate ulcerative colitis. Twenty-two adults who still had active disease despite TNF inhibitor treatment received spesolimab or a placebo…

This early-stage trial tested an experimental drug called BI 3006337 in 64 adults who are overweight or obese and have fatty liver disease. Participants received weekly injections of either the drug or a placebo for about 4 months. The main goal was to check safety and tolerabili…

This study tested whether spesolimab, a drug already approved for another skin condition, can help people with moderate to severe hidradenitis suppurativa (HS), a painful skin disease that causes abscesses and tunnels. 209 adults participated, receiving either spesolimab or a pla…

This study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…

This study tested a drug called BI 770371 in 28 people with compensated cirrhosis caused by MASH, a liver disease linked to metabolism. Participants received either the drug or a placebo as an infusion every 3 weeks for 12 weeks. The main goal was to see how well the drug is tole…

This completed study monitored 425 Japanese patients with progressive fibrosing interstitial lung disease (PF-ILD) who were prescribed Ofev capsules. The main goal was to track side effects, especially liver problems, in everyday medical practice. Researchers recorded any adverse…

This completed study monitored 1200 Japanese patients with chronic heart failure who took JARDIANCE® (empagliflozin) daily for a long time. Researchers tracked side effects like low blood sugar, dehydration, and kidney problems, as well as deaths and hospitalizations. The goal wa…

This early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…

This study tests an experimental oral drug, BI 1819479, in 322 adults with idiopathic pulmonary fibrosis (IPF). Participants receive one of three doses or a placebo for 6 to 12 months. The main goal is to see if the drug can slow the yearly decline in lung function, measured by b…

This Phase 3 trial tested survodutide, a weekly injection, in 218 adults with NASH (a fatty liver disease) and overweight or obesity. Participants received either survodutide or a placebo for 48 weeks, plus diet and exercise advice. The study measured whether the drug reduced liv…

This study tested a drug called spesolimab in 59 adults with palmoplantar pustulosis, a painful skin condition causing pustules on hands and feet. Participants received low or high doses of the drug or a placebo for 12 weeks. The main goal was to see if the drug safely reduced pu…

This study tested a new medicine called survodutide (BI 456906) to help people with obesity or overweight lose weight. Over 700 adults without type 2 diabetes received either the drug or a placebo injection once a week for about a year and a half, along with diet and exercise adv…

This Phase 2 trial tested a drug called spesolimab (BI 655130) in 51 adults with moderate to severe atopic dermatitis (eczema). Participants received either the drug or a placebo intravenously. The study measured how much eczema severity changed over 16 weeks using the EASI score…

This early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs th…

This early-stage trial tested two experimental drugs, BI 765049 and ezabenlimab, in 67 adults with advanced solid tumors like colorectal, lung, and pancreatic cancer. The main goal was to find the highest safe dose. Participants received the drugs by infusion every three weeks fo…

This study monitored 52 Japanese patients with generalized pustular psoriasis (GPP) who received spesolimab for acute symptoms. Researchers tracked side effects and disease activity in everyday clinical settings, not a controlled lab environment. The goal was to see how well the …

This study tested two or three drugs together in adults with advanced solid tumors (cancers that have spread). The main goal was to find the safest dose and see if the combination can shrink tumors. Participants took brigimadlin pills and received ezabenlimab infusions every 3 we…

This study tested a new cancer pill, brigimadlin, against standard chemo (doxorubicin) in 400 adults with advanced dedifferentiated liposarcoma. Participants took either the pill or received chemo infusions every 3 weeks. The goal was to see which treatment better slowed tumor gr…

This program in China gave a single infusion of spesolimab to 39 people with a severe skin condition called generalized pustular psoriasis (GPP) during a flare-up. Participants had no other treatment options available. The goal was to control the flare and monitor for side effect…

This study tested a new medicine called BI 1015550 in 1178 adults with progressive fibrosing interstitial lung diseases (PF-ILDs), a condition where lung tissue scars and worsens over time. Participants took either a low or high dose of the drug or a placebo twice daily for at le…

This study tested a drug called spesolimab in 27 adults with Crohn's disease who also have fistulas near the anus. The drug is given by IV every 4 weeks for 24 weeks. The study had two parts: first, researchers took tissue samples to learn what causes the fistulas; second, they c…

This study tested whether the drug spesolimab can help people with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps and boils. 52 adults were randomly assigned to receive either spesolimab or a placebo for about 3 months. Doctors counted…

This study tested a daily oral drug called afatinib against weekly intravenous methotrexate in 340 people with advanced head and neck cancer that had worsened after platinum-based chemotherapy. The main goal was to see which drug better delayed cancer growth. Researchers also loo…

This early-stage study tested a new drug called BI 765049, alone or combined with another drug (ezabenlimab), in 21 Asian adults with advanced solid tumors (stomach, colorectal, pancreatic, liver, head and neck, or lung cancer) that have a specific marker called B7-H6. The main g…

This study tested three different doses of a drug called BI 655064 in 121 people with active lupus nephritis, a serious kidney condition caused by lupus. The goal was to see if adding this drug to standard treatment could improve kidney function after one year. The trial compared…

This study tested a new medicine, BI 764198, in 67 adults with a kidney disease called FSGS. Participants took different doses of the medicine or a placebo daily for 12 weeks. The goal was to see if the medicine could reduce protein in the urine, a sign of better kidney health. T…

This study tested a new medicine called survodutide (BI 456906) to help people with overweight or obesity and type 2 diabetes lose weight. About 755 adults took part, receiving either the drug or a placebo as a weekly injection for 76 weeks, along with diet and exercise advice. T…

This study looked at the long-term safety of a drug called spesolimab in adults with moderate to severe ulcerative colitis who had already finished earlier trials. Researchers tracked side effects and checked if patients achieved remission over about 6.5 years. The goal was to se…

This early-stage study tested a new drug (BI 836880) alone and with another drug (BI 754091) in 21 Japanese patients with advanced solid tumors. The main goal was to find the safest dose and check for side effects. This is not a cure, but a step toward better controlling advanced…

This study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…

This study tested a new medicine called BI 1291583 in 22 adults with cystic fibrosis bronchiectasis, a lung condition that causes coughing and infections. Participants took one tablet daily for 12 weeks, and the study checked if the medicine was safe and well-tolerated. The trial…

This study tested a new cancer pill called brigimadlin in 138 adults with a rare type of fat-tissue cancer (dedifferentiated liposarcoma). The pill works by blocking a protein that helps the cancer grow. Participants took the pill once every three weeks, and doctors monitored sid…

This study tested a new drug called spesolimab in 98 adults with moderate-to-severe ulcerative colitis who did not get better with other biologic treatments. The goal was to see if the drug could safely reduce symptoms and help the colon heal. The trial was completed and looked a…

This early-phase trial tested a new drug called BI 836880 in 24 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Researchers also looked at how the drug moves through the bo…

This study tested a new medicine called survodutide for weight loss in 274 Japanese adults with obesity and related health problems like diabetes or high blood pressure. Participants received weekly injections of survodutide or a placebo for about 1.5 years, along with diet and e…

This study looked at the long-term safety of a medicine called nintedanib in children and teenagers with a rare lung condition that causes scarring (fibrosing interstitial lung disease). All 54 participants took nintedanib capsules twice a day for at least 1.5 to 3 years. The goa…

This study tested a single dose of spesolimab in 53 people with a rare, severe form of psoriasis called generalized pustular psoriasis (GPP) during a sudden flare. The goal was to see if the drug could quickly clear visible pustules compared to a placebo. Results showed that spes…

This study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…

This study tested a combination of two experimental drugs (BI 836880 and ezabenlimab) in 252 adults with advanced non-squamous lung cancer and other solid tumors. The first part found the safest dose; the second part checked if the combo could shrink tumors. Participants received…

This early-stage study tested a new oral drug, BI 3706674, in 47 adults with advanced stomach or esophageal cancer that had not responded to prior treatments. The goal was to find a safe dose and see if the drug could shrink tumors by blocking growth signals. The study is now com…

This study tested a medicine called Avenciguat (BI 685509) in 214 adults with scleroderma, a disease that can cause skin hardening and lung or blood vessel damage. Participants took either the study drug or a placebo three times daily for at least 11 months. Researchers measured …

This study looked at the long-term safety and effectiveness of the drug spesolimab for adults with hidradenitis suppurativa (HS), a painful skin condition. Participants who had already completed a previous spesolimab trial received injections every two weeks for two years. The go…

This study tested a new medicine called BI 1015550 in over 1,100 adults with idiopathic pulmonary fibrosis (IPF), a serious lung disease. Participants took either the study drug or a placebo twice daily for at least a year. The main goal was to see if the drug could slow the decl…

This early-phase trial tested a new drug called BI 836880 in 29 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to find a safe dose and check for side effects. The study was not designed to cure cancer, but to gather information …

This study tested a new medicine called survodutide in 307 Chinese adults with obesity or overweight. Participants received weekly injections of either survodutide or a placebo for about 19 months. The main goals were to see how much weight people lost and if at least 5% of body …

This study tested four different doses of an experimental drug (BI 655130) against a placebo in 152 adults with moderate to severe palmoplantar pustulosis (PPP), a skin condition causing painful pus-filled blisters on the palms and soles. The main goal was to see which dose best …

This study tested whether a monthly injection of spesolimab can prevent flare-ups of generalized pustular psoriasis (GPP), a rare and severe skin condition. 123 people aged 12 to 75 with clear or nearly clear skin joined the trial. They received either one of three doses of speso…

This study tested whether a daily tablet called iclepertin can improve memory and learning in adults with schizophrenia. Over 600 participants took either the drug or a placebo for 26 weeks while continuing their usual schizophrenia medication. Researchers measured changes in cog…

This study followed 18 people in Spain with idiopathic pulmonary fibrosis (IPF) or other progressive lung scarring who were taking nintedanib (OFEV) and had developed diarrhea. The goal was to see if the diarrhea could be controlled after 12 weeks while staying on the full dose. …

This study tested an experimental drug called BI 1569912 in 243 adults aged 18–65 with major depression that didn't improve with previous treatments. Participants took either a low, medium, or high dose of the drug or a placebo once daily for 6 weeks, while continuing their usual…

This study tested whether a daily medicine called iclepertin can improve memory and thinking in adults with schizophrenia. Over 600 participants took either iclepertin or a placebo for 26 weeks, while continuing their usual schizophrenia medications. Researchers measured cognitiv…

This study looked at whether atomoxetine, a medication for ADHD, can reduce impulsive behavior in adults aged 18-45 with moderate ADHD. Researchers measured impulsivity using questionnaires after a single dose and after two weeks of daily treatment. The goal was to see if the dru…

This study tested a medicine called iclepertin to see if it improves memory and thinking in adults with schizophrenia. About 620 participants took either iclepertin or a placebo daily for 26 weeks, while continuing their usual schizophrenia medications. Researchers measured chang…

This study tested whether a new oral medicine, BI 1569912, can help adults aged 18 to 65 with major depressive disorder. 225 participants were randomly assigned to one of three doses of the drug or a placebo, taken daily for 6 weeks. Researchers measured changes in depression sym…

This early-stage study tested a new oral drug, BI 1015550, in 15 people with idiopathic pulmonary fibrosis (IPF) who were not taking other IPF medications. The main goal was to see if the drug is safe and tolerable. Researchers also measured how the drug moves through the body. T…

This early-stage trial tested the safety and how the body handles a single dose of the experimental drug BI 706321 in 73 healthy men. The study had two parts: one to check safety and drug levels after increasing doses, and another to compare different pill forms and the effect of…

This completed phase 1 trial enrolled 14 healthy male volunteers to see how the antifungal drug itraconazole changes the levels of an experimental drug called BI 706321 in the blood. Participants took BI 706321 alone and then again after several days of itraconazole. The study me…

This completed Phase 1 trial looked at whether multiple doses of Survodutide, a weight-loss drug, change how the body absorbs and processes three common drugs: bupropion (an antidepressant), caffeine, and midazolam (a sedative). Thirty-four otherwise healthy adults with overweigh…

This completed Phase 1 trial tested whether taking the antifungal itraconazole changes how the body processes a single dose of the experimental drug BI 1015550 (Nerandomilast). Sixteen healthy men received the drug alone and then again while on a 12-day course of itraconazole. Re…

This completed study looked at how safe and effective JARDIANCE (empagliflozin) is for Korean adults with chronic kidney disease when used in routine medical care. Researchers tracked 299 patients starting the drug for the first time, recording side effects and changes in a key k…

This early-phase trial tested the safety and how the body handles a single dose of the experimental drug BI 425809 (iclepertin) in 83 healthy men. Researchers compared different forms (drinking solution vs. tablet) and looked at whether food changes drug absorption. The goal was …

This completed Phase 1 trial in 14 healthy adults tested whether taking BI 764198 along with metformin changes how much metformin gets into the blood. Participants received both drugs together or metformin alone in a crossover design. The goal was to see if there is a drug intera…

This completed Phase 1 study tested how the antifungal drug fluconazole changes the levels of the experimental drug BI 425809 in the blood. Fifteen healthy men took a single dose of BI 425809 alone, and later took it while also taking fluconazole daily. The goal was to see if flu…

This study tested how taking the cancer drug zongertinib with a high-fat meal changes its absorption compared to taking it on an empty stomach. Sixteen healthy men each received a single dose under both conditions. The results will help guide dosing instructions for future trials…

This study tested how the drug BI 1584862 is handled by the body in people with different levels of liver function. 43 adults with mild, moderate, or severe liver problems, and some with healthy livers, took a single dose. Researchers measured drug levels in the blood and monitor…

This completed Phase 1 trial enrolled 13 healthy men to compare two oral formulations of the drug BI 1810631. Researchers also tested how taking the drug with food or after multiple doses of the acid-reducer rabeprazole changes its absorption. The goal is to guide future dosing a…

This study followed 158 adults with chronic fibrosing interstitial lung disease (a type of progressive lung scarring) who were starting treatment with nintedanib. Researchers wanted to see if changes in lung function (measured by forced vital capacity) over 52 weeks were linked t…

This early-stage trial tested the safety and how the body handles a single dose of an experimental drug called BI 425809 in 49 healthy Japanese and Chinese men. Participants received either the drug or a placebo, and researchers monitored side effects and drug levels in the blood…

This study looks at how the drug BI 1015550 is processed in people with mild or moderate liver problems compared to those with healthy livers. 28 adults will take a single dose and have their blood levels measured over time. The goal is to see if liver impairment changes drug exp…

This completed Phase 1 trial in 16 healthy men tested how taking carbamazepine (a strong enzyme inducer) changes the amount of zongertinib in the blood. Participants received a single dose of zongertinib alone, then later took increasing doses of carbamazepine for 18 days followe…

This early-stage trial tested the safety and tolerability of single doses of BI 3000202 tablets in 68 healthy men. It also looked at how food affects the drug's levels in the body. The study is complete and provides basic information for future research.

This completed phase 1 trial in 18 healthy adults examined how multiple doses of the experimental drug BI 1569912 change the way the body processes three common medications: repaglinide (for diabetes), midazolam (for sedation), and bupropion (for depression or smoking cessation).…

This early-phase study looked at how healthy men process and eliminate a single dose of the experimental drug BI 1015550. Six participants took a radioactive-labelled version of the drug so researchers could track its breakdown in urine and stool. The goal was to understand the d…

This study looks at how a single injection of BI 456906, a drug being developed for obesity and liver disease, behaves in the blood of people with different levels of kidney function. Researchers will compare drug levels in 42 adults with normal kidneys to those with mild, modera…

This completed Phase 1 trial in 32 healthy adults compared how two different combinations of vicadrostat and empagliflozin are absorbed by the body. It also looked at whether food changes drug levels. Participants received a single dose of each combination in random order. The go…

This early-phase trial tested the safety and tolerability of an experimental drug called BI 1569912 in 56 healthy Japanese men. Participants received either single or multiple doses of the drug or a placebo. The study aimed to see how the body processes the drug and if it causes …

This early-stage trial tested a single injection of the experimental drug BI 3006337 in 80 healthy men to see if it is safe and how the body processes it. Participants received either the drug or a placebo, and researchers monitored side effects and drug levels in the blood. Sinc…

This early-stage trial tested the safety and how the body handles multiple doses of an experimental drug called BI 425809 in 96 healthy young and elderly volunteers. Participants took the drug or a placebo daily for 12 days, and some also compared morning versus evening dosing. T…

This completed Phase 1 trial studied how the drug nerandomilast is processed in the bodies of 12 healthy Japanese men after a single dose. Participants took one tablet by mouth after fasting. The goal was to measure drug levels in the blood over time. This early-stage study does …

This completed Phase 1 trial looked at whether taking multiple doses of the experimental drug BI 1015550 (nerandomilast) changes how the body processes midazolam, a common sedative. Fifteen healthy men aged 18-55 took part. The goal was to see if BI 1015550 affects a key liver en…

This completed Phase 1 trial studied how the experimental drug BI 1291583 is broken down and removed from the body. Eight healthy men took a single oral dose containing a tiny radioactive marker. Researchers measured the drug and its breakdown products in blood, urine, and stool …

This completed Phase 1 trial enrolled 15 healthy adults to compare how the body absorbs two different tablet forms of nerandomilast, a drug being developed for lung conditions. It also looked at whether taking the new formulation with food changes its absorption. Participants rec…

This completed phase 1 trial enrolled 16 healthy adults to compare two formulations of the drug BI 456906 (Survodutide). Participants received a single injection of each version in random order. Researchers measured how much drug got into the blood and how quickly, to see if the …

This early-phase study looked at how the experimental drug BI 425809 (iclepertin) changes the way the body processes four common medications: midazolam, warfarin, omeprazole, and digoxin. Thirteen healthy men took these drugs with and without BI 425809 to see if there were any in…

This completed Phase 1 trial in 14 healthy men tested whether taking itraconazole (a common antifungal) changes how the body absorbs the experimental drug BI 3031185. Participants received a single dose of BI 3031185 alone, then later with multiple doses of itraconazole. The goal…

This study tested whether a pre-filled syringe and a pre-filled pen deliver the same amount of survodutide into the body. Fifty-six healthy or overweight adults received a single dose of each version in random order. Researchers measured drug levels in the blood to see if the two…

This study looked at how taking multiple doses of carbamazepine changes the way the body processes a single dose of nerandomilast. Sixteen healthy men aged 18 to 55 took part. The goal was to measure drug levels in the blood, not to treat any disease.

This study looked at how taking the drug BI 1015550 with or without food changes its levels in the blood. 18 healthy adults took a single dose under both conditions. The goal was to understand if food affects how the body absorbs the drug, which helps guide future dosing instruct…

This early-stage study looked at how a new drug called BI 425809 affects the way the body processes another medicine, midazolam. Fifteen healthy men took both drugs to see if BI 425809 changes how quickly midazolam is broken down. The goal was to understand potential drug interac…

This study looked at how the body absorbs empagliflozin, a diabetes medication, when taken as a whole tablet or dissolved in water and mixed with food. Fourteen healthy adults aged 18 to 55 took part. The goal was to measure drug levels in the blood to see if the two ways of taki…

This study looked at how different levels of kidney function affect the way the experimental brain drug iclepertin is processed in the body. 36 adults with and without kidney problems took a single dose of the drug. Researchers measured drug levels in the blood to see if kidney i…

This early-stage study tested a new drug called BI 1015550 in 16 healthy Japanese men to see if it is safe and how the body processes it. Participants received a single rising dose of the drug or a placebo. The goal was to check for side effects and measure drug levels in the blo…

This study checked whether a single dose of the experimental drug BI 1015550 causes any heart rhythm changes in healthy adults. Forty-six volunteers received low and high doses of the drug, a placebo, and an active control to compare effects. The goal was to gather safety informa…

This study involved 1304 adults with rheumatoid arthritis who had at least two risk factors for interstitial lung disease (ILD), such as being male, a smoker, or over 60. Researchers used CT scans to develop a prediction model that helps doctors decide who should be screened for …

This early-phase trial tested the safety and tolerability of an experimental drug called BI 1015550 in 42 healthy men. Participants received either single or multiple rising doses of the drug. The study aimed to understand how the body processes the drug and to check for side eff…

This study checked whether taking iclepertin (a drug being tested for other conditions) changes how the body handles a common birth control pill. Nineteen healthy women took the birth control pill with and without iclepertin, and researchers measured hormone levels in their blood…

This completed Phase 1 trial enrolled 14 healthy men to see how taking bosentan (a drug for high blood pressure in the lungs) changes the amount of BI 425809 (iclepertin) in the blood. Participants took BI 425809 alone for 10 days, then both drugs together for 14 days. The study …

This completed Phase 1 trial enrolled 15 healthy men to understand how the experimental drug zongertinib is absorbed, broken down, and eliminated from the body. In one part, participants took a radioactive oral solution so researchers could track the drug in urine and stool. In a…

This completed study in France tracked over 10,000 people with idiopathic pulmonary fibrosis to see how long they continued taking antifibrotic drugs (nintedanib or pirfenidone). The goal was to measure the percentage still on treatment after 30 months and identify factors linked…

This study looked at how the body processes four common drugs (rosuvastatin, digoxin, metformin, and furosemide) in healthy people and those with liver cirrhosis. Researchers measured drug levels in the blood to see if liver disease changes how these medicines are handled. The go…

This completed phase 1 trial in 16 healthy men looked at whether taking multiple doses of the cancer drug zongertinib changes how the body processes three common drugs: midazolam (a sedative), omeprazole (for heartburn), and repaglinide (for diabetes). Participants received zonge…

This early-stage study looked at how a new drug called BI 425809 moves from the blood into the spinal fluid in 25 healthy men. Researchers gave different doses and measured drug levels and safety. The goal was to understand the drug's behavior in the body, not to treat any diseas…

This completed Phase 1 study in 14 healthy men tested whether taking multiple doses of itraconazole changes the amount of BI 764198 in the blood after a single dose. Participants took BI 764198 alone and then again with itraconazole to compare drug levels. The goal is to understa…

This study looked at whether taking a new drug called BI 425809 with or without food changes how the body absorbs it. Sixteen healthy adults took the drug once with a meal and once on an empty stomach. The results will help doctors decide the best way to take this medicine in fut…

This study looked at how people with liver cirrhosis process five common medicines (caffeine, warfarin, omeprazole, metoprolol, and midazolam) compared to healthy individuals. Four adults—some healthy, some with mild or moderate cirrhosis—took single doses of each drug. Frequent …

This study looked at how the body absorbs an experimental drug called BI 1015550 when given in different pill forms and with or without food. Twenty-four healthy adults each took three single doses in random order. The goal was to compare the new commercial pill form to an older …

This study looked at how the drug BI 1015550 is processed in people with and without kidney problems. 26 adults took a single dose, and researchers measured drug levels in their blood. The goal was to see if kidney impairment changes how the drug is absorbed, to guide future dosi…

This study looked at how a new drug called BI 3000202 changes the way the body handles two other medicines: rosuvastatin (for cholesterol) and digoxin (for heart conditions). Fourteen healthy adults took part to help researchers understand if the new drug could affect how these m…

This study in 8 healthy men aims to understand how the experimental drug BI 1584862 is absorbed, broken down, and eliminated from the body. Participants take a single oral dose with a radioactive tracer and a tiny intravenous dose with a stable isotope. Researchers measure the dr…

This study tested three different tablet versions of the drug BI 425809 in 18 healthy adults to see how well the body absorbs each one. Participants took a single dose of each version in random order, and researchers measured drug levels in the blood. The goal was to compare the …

This study looked at how the experimental drug BI 3000202 is processed and removed from the body. In one part, 12 healthy adults took the drug as a liquid, and researchers measured how much came out in urine and stool. In another part, they compared taking a tablet versus getting…

This early-stage trial tested the safety and how the body processes multiple doses of an investigational drug called BI 3810477. It involved 47 healthy adults aged 18 to 60. The study did not aim to treat any disease, but to gather important safety information for future research…

This study looked at how the antibiotic rifampicin changes the way the body processes an experimental drug called BI 425809. Sixteen healthy men took a single dose of BI 425809 alone and then again after several days of rifampicin. The goal was to measure drug levels in the blood…

This study looked at how a new drug, zongertinib, changes the way other common drugs (dabigatran, rosuvastatin, metformin, and furosemide) are processed in the body. It involved 32 healthy men who took these drugs with and without zongertinib. The goal was to measure drug levels …

This study looked at how taking multiple doses of itraconazole, a common antifungal, changes the way the body handles a single dose of zongertinib, a potential cancer drug. Sixteen healthy men participated to measure drug levels in the blood. The goal was to understand drug inter…

This study looked at how much of the experimental drug BI 425809 enters the bloodstream after being taken by mouth. Six healthy men received a single oral tablet and a tiny intravenous tracer dose. The goal was purely to gather information on the drug's absorption, not to treat a…

This study tested a new drug called BI 3034701 for the first time in humans. It involved 125 healthy men and people with overweight or obesity to see how safe the drug is and how it moves through the body. Participants received either the drug or a placebo as an injection under t…

This study looked at how healthy men absorb, break down, and eliminate a single dose of an experimental drug called BI 764198. Twenty-four men took the drug by mouth, and researchers measured the drug and its breakdown products in blood, urine, and stool over several days. The go…

This study looked at how taking bosentan (a drug that can speed up liver breakdown of other drugs) changes the amount of nerandomilast in the blood. Sixteen healthy men took nerandomilast alone and then again after several days of bosentan. The goal was to see if bosentan lowers …

This study looked at how the experimental drug BI 1569912 is absorbed, broken down, and removed from the body. Eight healthy men took a single oral dose with a radioactive tracer, plus a tiny intravenous dose with a different tracer. The goal was to measure how much of the drug e…

This study tested whether two different manufacturing versions of the drug zongertinib are absorbed the same way in the body. Fifty-six healthy adults took a single dose of each version at different times. The goal was to see if the two versions are bioequivalent, meaning they pr…

This early-stage study looked at how a new drug, BI 655130, enters the body when given as a shot under the skin compared to through an IV. 36 healthy adults took part to measure drug levels in the blood. The goal was to understand the drug's behavior, not to treat any disease.

This study tested a new drug called BI 1015550 in 24 healthy Chinese adults (ages 18–55). The goal was to see how the drug is processed by the body and whether it is safe. Participants received a single dose and were monitored for side effects. This is an early-stage trial with n…

This early-stage study looked at how taking the experimental drug BI 1015550 with or without food changes its absorption in the body. Twelve healthy men aged 18 to 55 participated. The goal was to understand the best way to take the drug, not to treat any disease.

This early-stage study looked at how taking multiple doses of an experimental drug (BI 1015550) changes the way the body handles two approved lung medications (nintedanib and pirfenidone). Fourteen healthy men received the drugs in a fixed order, and researchers measured drug lev…

This early-stage study tested a new drug called BI 3006337 in 36 healthy Japanese men to see if it is safe and how the body handles it. Participants received either a single shot or multiple shots over 6 weeks. The goal was to measure side effects and drug levels in the blood, no…

This study checked if two different pill versions of the drug nerandomilast are absorbed the same way in the body. It involved 64 healthy adults who took a single dose of each version at different times. The goal was to confirm the new version works just like the one used in late…

This study looked at how taking the antifungal drug itraconazole changes the amount of a new drug (BI 1815368) in the blood. Fourteen healthy men took the new drug alone and then again with itraconazole. The goal was to see if itraconazole increases the drug's levels, which could…

This study looked at how three different forms of the experimental drug BI 456906 are absorbed in the body. Thirty healthy adults each received a single dose of all three versions in random order. The goal was to see if the newer forms work similarly to the original, not to treat…

This study looked at how a new drug, BI 655130, enters the bloodstream when injected in different places (belly or thigh) and in different amounts. 48 healthy adults took part. The goal was to learn about the drug's absorption, not to treat any disease.

This study looked at how a common antifungal drug, itraconazole, changes the levels of an experimental drug called BI 1584862 in the blood. Fourteen healthy men took BI 1584862 alone and then again with itraconazole to see if the combination altered drug exposure. The results wil…

This study tested whether two different versions of the drug nerandomilast are processed the same way in the body. 64 healthy adults each took a single dose of both formulations at different times. The goal was to see if the new formulation works just like the one used in later-s…

This study looked at 88 adults with connective tissue disease-related lung scarring who were prescribed nintedanib. Researchers measured changes in lung function and tracked cough and breathlessness using a questionnaire over 24 months. The goal was to see if improvements in lung…

This study looked at how a new cancer drug (BI 907828) interacts with two other medicines: rifampicin (an antibiotic) and itraconazole (an antifungal). Thirty-three adults with advanced solid tumors who had no other treatment options took BI 907828 alone and then with one of the …

This study looked at how much of the drug BI 1015550 gets into the blood after taking it by mouth compared to directly into a vein. Eight healthy men took the drug as a pill and also received a tiny radioactive tracer dose. The goal was to understand the drug's absorption and pro…

This study looked at how a common antibiotic (erythromycin) changes the levels of an experimental drug called BI 1291583 in the body. Twenty healthy adults took both drugs in a fixed order to measure the effect. The goal was purely to gather information on drug interactions, not …

This study gave 6 healthy men a single dose of the experimental drug BI 425809 (with a radioactive tracer) to see how it moves through the body. Researchers measured how much of the drug came out in urine and stool, and how fast. The goal was to understand the drug's metabolism a…

This small study tested an experimental drug called BI 655130 in 8 adults with moderate to severe ulcerative colitis who had not tried biologic treatments before. The main goal was to understand how the drug works at the gene level, not to prove it cures or controls the disease. …

This study looked at how the experimental drug iclepertin (BI 425809) is processed in people with and without liver problems. 29 adults aged 18-79 took a single dose of the drug. Researchers measured drug levels in the blood and monitored safety to see if liver impairment changes…